Cargando…
Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatme...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296090/ https://www.ncbi.nlm.nih.gov/pubmed/37371715 http://dx.doi.org/10.3390/biomedicines11061620 |
_version_ | 1785063575425908736 |
---|---|
author | Dara, Praneet Farooqui, Zeba Mwale, Fackson Choe, Chungyoul van Wijnen, Andre J. Im, Hee-Jeong |
author_facet | Dara, Praneet Farooqui, Zeba Mwale, Fackson Choe, Chungyoul van Wijnen, Andre J. Im, Hee-Jeong |
author_sort | Dara, Praneet |
collection | PubMed |
description | Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatments for either rheumatoid arthritis (RA) or osteoarthritis (OA) is to reduce pain. Non-steroidal anti-inflammatory drugs, opioids, and opioid antagonists have each been considered in the management of chronic pain in arthritis patients. Naltrexone is an oral-activated opioid antagonist with biphasic dose-dependent pharmacodynamic effects. The molecule acts as a competitive inhibitor of opioid receptors at high doses. However, naltrexone at low doses has been shown to have hormetic effects and provides relief for chronic pain conditions such as fibromyalgia, multiple sclerosis (MS), and inflammatory bowel disorders. Current knowledge of naltrexone suggests that low-dose treatments may be effective in the treatment of pain perception in chronic inflammatory conditions observed in patients with either RA or OA. In this review, we evaluated the therapeutic benefits of low-dose naltrexone (LDN) on arthritis-related pain conditions. |
format | Online Article Text |
id | pubmed-10296090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102960902023-06-28 Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases Dara, Praneet Farooqui, Zeba Mwale, Fackson Choe, Chungyoul van Wijnen, Andre J. Im, Hee-Jeong Biomedicines Review Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatments for either rheumatoid arthritis (RA) or osteoarthritis (OA) is to reduce pain. Non-steroidal anti-inflammatory drugs, opioids, and opioid antagonists have each been considered in the management of chronic pain in arthritis patients. Naltrexone is an oral-activated opioid antagonist with biphasic dose-dependent pharmacodynamic effects. The molecule acts as a competitive inhibitor of opioid receptors at high doses. However, naltrexone at low doses has been shown to have hormetic effects and provides relief for chronic pain conditions such as fibromyalgia, multiple sclerosis (MS), and inflammatory bowel disorders. Current knowledge of naltrexone suggests that low-dose treatments may be effective in the treatment of pain perception in chronic inflammatory conditions observed in patients with either RA or OA. In this review, we evaluated the therapeutic benefits of low-dose naltrexone (LDN) on arthritis-related pain conditions. MDPI 2023-06-02 /pmc/articles/PMC10296090/ /pubmed/37371715 http://dx.doi.org/10.3390/biomedicines11061620 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dara, Praneet Farooqui, Zeba Mwale, Fackson Choe, Chungyoul van Wijnen, Andre J. Im, Hee-Jeong Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases |
title | Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases |
title_full | Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases |
title_fullStr | Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases |
title_full_unstemmed | Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases |
title_short | Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases |
title_sort | opiate antagonists for chronic pain: a review on the benefits of low-dose naltrexone in arthritis versus non-arthritic diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296090/ https://www.ncbi.nlm.nih.gov/pubmed/37371715 http://dx.doi.org/10.3390/biomedicines11061620 |
work_keys_str_mv | AT darapraneet opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases AT farooquizeba opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases AT mwalefackson opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases AT choechungyoul opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases AT vanwijnenandrej opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases AT imheejeong opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases |